Invictus MD Provides Update on ACMPR Sales License Amendment as it Prepares for Legalization

Posted on Categories: Investor Relations

Vancouver, BC, November 27, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1), through its interests in two Access to Cannabis for Medical Purposes Regulations (“ACMPR“) license holders, its wholly-owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms”) and its one-third interest in AB Laboratories Inc. (“AB Labs”), continues to execute plans that will achieve production capacity of 6,000 kg commencing January 2018, several months before Canada expects cannabis to become recreationally legal. Total current annual production capacity at both locations is approximately 1,500 kg.

As announced on October 27, 2017, Health Canada had removed previously disclosed production capacity restrictions at both Acreage Pharms and AB Labs.

Read more “Invictus MD Provides Update on ACMPR Sales License Amendment as it Prepares for Legalization”

Invictus MD Strengthens Management Team With Appointment of New CFO

Posted on Categories: Investor Relations

Vancouver, BC, November 6, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1), is pleased to announce the appointment of Dylan Easterbrook as Chief Financial Officer.

Mr. Easterbrook is a seasoned accounting and financial professional, who most recently was controller of a publicly traded global fibre optic connectivity solution provider. Prior to that role he was with Ernst & Young, one of the largest professional services firms in the world and one of the Big Four accounting firms, where he led audit engagements for both public and privately held companies from a variety of industries, including the emerging markets.

Dylan is a Canadian Chartered Professional Accountant (CPA, CA), and also holds a Bachelor of Science in Life Sciences degree from the University of British Columbia.

Read more “Invictus MD Strengthens Management Team With Appointment of New CFO”

Invictus MD prepares for legalization with expected cannabis ready production of 6,000 kg

Posted on Categories: Investor Relations

Vancouver, BC, October 27, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1), through its interests in two Access to Cannabis for Medical Purposes Regulations (“ACMPR“) license holders, its wholly-owned subsidiary Acreage Pharms Ltd. (“Acreage Pharms”) and its one-third interest in AB Laboratories Inc. (“AB Labs”), expects to have production capacity of 6,000 kg commencing January 2018, several months before Canada expects cannabis to become recreationally legal. Total current production capacity at both locations is approximately 1,500 kg.

License Capacity and Term

Health Canada has removed the previously disclosed production capacity restrictions at both Acreage Pharms and AB Labs. In addition, AB Labs received an extension of its existing ACMPR license for a period of two years and Acreage Pharms’ ACMPR license was extended through to March 2020.

Read more “Invictus MD prepares for legalization with expected cannabis ready production of 6,000 kg”

Invictus MD Updates Shareholders on Cannabis Legalization Process

Posted on Categories: Investor Relations

Vancouver, BC, October 17, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS1) Today, Invictus MD updated shareholders that it is taking steps to monitor the government policy development process in advance of the legalization of recreational cannabis that is expected in July 2018.

“There are a number of authorities across the country that are developing policies and regulations to support the successful legalization of recreational cannabis. Invictus MD is monitoring these jurisdictions and will engage officials when necessary,” stated Dan Kriznic, Chairman and CEO of Invictus MD.

Read more “Invictus MD Updates Shareholders on Cannabis Legalization Process”